Zepp Health Corporation Reports 3.6% Revenue Decrease and $19.7M Net Loss in Q1 2025, Adjusted Net Loss at $18.1M

Reuters
05-20
Zepp Health Corporation Reports 3.6% Revenue Decrease and $19.7M Net Loss in Q1 2025, Adjusted Net Loss at $18.1M

Zepp Health Corporation reported its financial results for the first quarter of 2025, revealing a revenue of $38.5 million, which marks a 3.6% decline from the first quarter of 2024. This decrease was primarily attributed to a $5.0 million reduction in the sales of Xiaomi wearable products. However, the sales of Amazfit-branded products showed a positive growth trend with a 10.2% increase year over year. The company experienced a net loss of $19.7 million for the first quarter of 2025, compared to a net loss of $14.8 million in the corresponding period of 2024. The adjusted net loss, which excludes specific non-GAAP adjustments, stood at $18.1 million, a rise from the adjusted net loss of $13.6 million in the first quarter of 2024. Looking ahead, Zepp Health projects second-quarter revenues to range between $50 million and $55 million, indicating an anticipated growth of 23% to 35% compared to the second quarter of 2024. The company also highlighted a significant shift in its debt structure, with long-term borrowings now comprising about 70% of the total debt, following the retirement of $67.8 million of debt since early 2023 and an additional $11.5 million repaid in the first quarter of 2025. The ongoing share-repurchase program reflects confidence in the company's future outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CN90888) on May 20, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10